Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection.

Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection.
复制标题

结合 gp120 结合蛋白和 gp41 结合抗体产生协同效应,灭活 HIV-1 病毒粒子并抑制 HIV-1 感染。

DOI:
10.3390/molecules26071964
复制
发表时间:
2021-03-31
期刊:
Molecules (Basel, Switzerland)
影响因子:
--
通讯作者:
Jiang S
Jiang S
中科院分区:
其他
文献类型:
--
作者:
Wang X;Cao M;Wu Y;Xu W;Wang Q;Ying T;Lu L;Jiang S

文献摘要

参考文献

相似文献

Acquired immune deficiency syndrome (AIDS) has prevailed over the last 30 years. Although highly active antiretroviral therapy (HAART) has decreased mortality and efficiently controlled the progression of disease, no vaccine or curative drugs have been approved until now. A viral inactivator is expected to inactivate cell-free virions in the absence of target cells. Previously, we identified a gp120-binding protein, mD1.22, which can inactivate laboratory-adapted HIV-1. In this study, we have found that the gp41 N-terminal heptad repeat (NHR)-binding antibody D5 single-chain variable fragment (scFv) alone cannot inactivate HIV-1 at the high concentration tested. However, D5 scFv in the combination could enhance inactivation activity of mD1.22 against divergent HIV-1 strains, including HIV-1 laboratory-adapted strains, primary HIV-1 isolates, T20- and AZT-resistant strains, and LRA-reactivated virions. Combining mD1.22 and D5 scFv exhibited synergistic effect on inhibition of infection by divergent HIV-1 strains. These results suggest good potential to develop the strategy of combining a gp120-binding protein and a gp41-binding antibody for the treatment of HIV-1 infection.
DOI: 10.1038/nature11544
发表时间: 2012-11-15
期刊: Nature
影响因子: 64.8
作者:
Huang J;Ofek G;Laub L;Louder MK;Doria-Rose NA;Longo NS;Imamichi H;Bailer RT;Chakrabarti B;Sharma SK;Alam SM;Wang T;Yang Y;Zhang B;Migueles SA;Wyatt R;Haynes BF;Kwong PD;Mascola JR;Connors M
通讯作者: Connors M
在基于肽的 HIV-1 融合抑制剂中添加人工尾锚以提高其效力和耐药性。
DOI: 10.3390/molecules22111996
发表时间: 2017-11-20
期刊: Molecules (Basel, Switzerland)
影响因子: --
作者:
Su S;Ma Z;Hua C;Li W;Lu L;Jiang S
通讯作者: Jiang S
HIV-1 gp41 靶向融合抑制肽增强 gp120 靶向蛋白介导的 HIV-1 病毒颗粒失活
DOI: 10.1038/emi.2017.46
发表时间: 2017-06-21
影响因子: 13.2
作者:
Qi Q;Wang Q;Chen W;Du L;Dimitrov DS;Lu L;Jiang S
通讯作者: Jiang S
DOI: 10.1126/science.6189183
发表时间: 1983-01-01
期刊: SCIENCE
影响因子: 56.9
作者:
BARRESINOUSSI, F;CHERMANN, JC;MONTAGNIER, L
通讯作者: MONTAGNIER, L
DOI: 10.1038/nature14264
发表时间: 2015-03-05
期刊: NATURE
影响因子: 64.8
作者:
Gardner, Matthew R.;Kattenhorn, Lisa M.;Kondur, Hema R.;von Schaewen, Markus;Dorfman, Tatyana;Chiang, Jessica J.;Haworth, Kevin G.;Decker, Julie M.;Alpert, Michael D.;Bailey, Charles C.;Neale, Ernest S., Jr.;Fellinger, Christoph H.;Joshi, Vinita R.;Fuchs, Sebastian P.;Martinez-Navio, Jose M.;Quinlan, Brian D.;Yao, Annie Y.;Mouquet, Hugo;Gorman, Jason;Zhang, Baoshan;Poignard, Pascal;Nussenzweig, Michel C.;Burton, Dennis R.;Kwong, Peter D.;Piatak, Michael, Jr.;Lifson, Jeffrey D.;Gao, Guangping;Desrosiers, Ronald C.;Evans, David T.;Hahn, Beatrice H.;Ploss, Alexander;Cannon, Paula M.;Seaman, Michael S.;Farzan, Michael
通讯作者: Farzan, Michael